The effect of the DASH diet in patients with type 2 diabetes
- Conditions
- Diabetes mellitus.Non-insulin-dependent diabetes mellitus
- Registration Number
- IRCT2017021432571N1
- Lead Sponsor
- rmia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Criteria for inclusion in the study: Suffering from diabetes type 2; Not Suffering from any diabetic complications such as nephropathy, retinopathy, neuropathy and cardiovascular complications; Aged between 18 to 65; Consumption of same drugs (glibenclamide, metformin).
Criteria for exclusion from the study: Suffering from diabetes type 1; Insulin Therapy; Suffering from liver diseases; Suffering from renal diseases; Suffering from thyroid disease; Pregnancy and lactation; Smoking and drinking alcohol; Consumption of drugs reducing blood fat and pressure and Weight, thiazide diuretics and corticosteroids; Change of type and dosage of consuming drugs during the study; Consumption of Herbal or chemical supplements; Suffering from Electrolyte abnormalities and Digestive diseases associated with malabsorption; Gastric bypass surgery and cholecystectomy.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total cholesterol. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: enzymatic method, mg/dl.;Triglyceride. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: enzymatic method, mg/dl.;HDL cholesterol. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: enzymatic method, mg/dl.;LDL cholesterol. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: enzymatic method, mg/dl.;VLDL cholesterol. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: Triglyceride/5, if TG>400: VLDL-C = TC – (HDL-C + LDL-C), mg/dl.;Free Fatty Acid. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: ELISA method, nmol/ml.;Weight. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: Inbody770 Body Analyzer, kg.
- Secondary Outcome Measures
Name Time Method Systolic blood pressure. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Body composition analysis (Fat mass, Fat free mass, Body water, Body cell mass, Skeletal muscle mass). Timepoint: Before Intervention and 12 weeks after Intervention. Method of measurement: Inbody770 Body Analyzer, Bioelectrical impedance analysis.